Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Pockets of HIV Non-infection Within Highly-Infected Risk Networks in Athens, Greece.

Williams LD, Kostaki EG, Pavlitina E, Paraskevis D, Hatzakis A, Schneider J, Smyrnov P, Hadjikou A, Nikolopoulos GK, Psichogiou M, Friedman SR.

Front Microbiol. 2018 Aug 24;9:1825. doi: 10.3389/fmicb.2018.01825. eCollection 2018.

2.

HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.

Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A.

PLoS One. 2018 Aug 16;13(8):e0202109. doi: 10.1371/journal.pone.0202109. eCollection 2018.

3.

An innovative study design to assess the community effect of interventions to mitigate HIV epidemics using transmission-chain phylodynamics.

Magiorkinis G, Karamitros T, Vasylyeva TI, Williams LD, Mbisa JL, Hatzakis A, Paraskevis D, Friedman SR.

Am J Epidemiol. 2018 Aug 7. doi: 10.1093/aje/kwy160. [Epub ahead of print]

PMID:
30101288
4.

Unravelling the history of hepatitis B virus genotypes A and D infection using a full-genome phylogenetic and phylogeographic approach.

Kostaki EG, Karamitros T, Stefanou G, Mamais I, Angelis K, Hatzakis A, Kramvis A, Paraskevis D.

Elife. 2018 Aug 7;7. pii: e36709. doi: 10.7554/eLife.36709.

5.
6.

The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.

Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M.

Semin Liver Dis. 2018 Aug;38(3):181-192. doi: 10.1055/s-0038-1666841. Epub 2018 Jul 9.

PMID:
29986353
7.

Impact of Interferon-α Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Karamitros T, Papatheodoridis G, Paraskevis D, Hatzakis A, Mbisa JL, Georgopoulou U, Klenerman P, Magiorkinis G.

Front Immunol. 2018 Apr 16;9:777. doi: 10.3389/fimmu.2018.00777. eCollection 2018.

8.

Molecular Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals in a Network-Based Intervention (Transmission Reduction Intervention Project): Phylogenetics Identify HIV-1-Infected Individuals With Social Links.

Kostaki EG, Nikolopoulos GK, Pavlitina E, Williams L, Magiorkinis G, Schneider J, Skaathun B, Morgan E, Psichogiou M, Daikos GL, Sypsa V, Smyrnov P, Korobchuk A, Malliori M, Hatzakis A, Friedman SR, Paraskevis D.

J Infect Dis. 2018 Jul 24;218(5):707-715. doi: 10.1093/infdis/jiy239.

PMID:
29697829
9.

Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Tsiara CG, Nikolopoulos GK, Dimou NL, Pantavou KG, Bagos PG, Mensah B, Talias M, Braliou GG, Paraskeva D, Bonovas S, Hatzakis A.

J Genet. 2018 Mar;97(1):235-251.

10.

Molecular investigation of HIV-1 cross-group transmissions during an outbreak among people who inject drugs (2011-2014) in Athens, Greece.

Paraskevis D, Nikolopoulos GK, Sypsa V, Psichogiou M, Pantavou K, Kostaki E, Karamitros T, Paraskeva D, Schneider J, Malliori M, Friedman SR, Des Jarlais DC, Daikos GL, Hatzakis A.

Infect Genet Evol. 2018 Apr 10;62:11-16. doi: 10.1016/j.meegid.2018.04.010. [Epub ahead of print]

PMID:
29653216
11.

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.

Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP.

J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. doi: 10.1111/jvh.12875. Review.

PMID:
29508946
12.

Spatiotemporal Characteristics of the HIV-1 CRF02_AG/CRF63_02A1 Epidemic in Russia and Central Asia.

Kostaki EG, Karamitros T, Bobkova M, Oikonomopoulou M, Magiorkinis G, Garcia F, Hatzakis A, Paraskevis D.

AIDS Res Hum Retroviruses. 2018 May;34(5):415-420. doi: 10.1089/AID.2017.0233. Epub 2018 Apr 5.

PMID:
29455562
13.

Molecular epidemiology reveals the role of war in the spread of HIV in Ukraine.

Vasylyeva TI, Liulchuk M, Friedman SR, Sazonova I, Faria NR, Katzourakis A, Babii N, Scherbinska A, Thézé J, Pybus OG, Smyrnov P, Mbisa JL, Paraskevis D, Hatzakis A, Magiorkinis G.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1051-1056. doi: 10.1073/pnas.1701447115. Epub 2018 Jan 16.

14.

Knowledge, Normative Beliefs and Attitudes Related to Recent HIV Infection among People who Inject Drugs in Athens, Greece.

Giannou F, Nikolopoulos GK, Pantavou K, Benetou V, Kantzanou M, Sypsa V, Williams LD, Friedman SR, Hatzakis A.

Curr HIV Res. 2017;15(6):386-395. doi: 10.2174/1570162X15666171122165636.

PMID:
29173178
15.

Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P.

J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

16.

Detailed Molecular Surveillance of the HIV-1 Outbreak Among People who Inject Drugs (PWID) in Athens During a Period of Four Years.

Kostaki E, Magiorkinis G, Psichogiou M, Flampouris A, Iliopoulos P, Papachristou E, Daikos GL, Bonovas S, Otelea D, Friedman SR, Hatzakis A, Paraskevis D.

Curr HIV Res. 2017;15(6):396-404. doi: 10.2174/1570162X15666171120104048.

PMID:
29165088
17.

Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health.

Paraskevis D, Kostaki E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, Skoutelis A, Papastamopoulos V, Paraskeva D, Antoniadou A, Papadopoulos A, Psichogiou M, Daikos GL, Chrysos G, Paparizos V, Kourkounti S, Sambatakou H, Sipsas NV, Lada M, Panagopoulos P, Maltezos E, Drimis S, Hatzakis A.

Genes (Basel). 2017 Nov 13;8(11). pii: E322. doi: 10.3390/genes8110322.

18.

Estimating HCV disease burden-volume 4 (editorial).

Dore GJ, Hatzakis A, Negro F, Waked I.

J Viral Hepat. 2017 Oct;24 Suppl 2:4-7. doi: 10.1111/jvh.12763.

PMID:
29105284
19.

Molecular Tracing of the Geographical Origin of Human Immunodeficiency Virus Type 1 Infection and Patterns of Epidemic Spread Among Migrants Who Inject Drugs in Athens.

Paraskevis D, Kostaki E, Nikolopoulos GK, Sypsa V, Psichogiou M, Del Amo J, Hodges-Mameletzis I, Paraskeva D, Skoutelis A, Malliori M, Williams L, Friedman SR, Daikos GL, Hatzakis A.

Clin Infect Dis. 2017 Nov 29;65(12):2078-2084. doi: 10.1093/cid/cix717.

PMID:
29020180
20.

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele.

Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D.

Pharmgenomics Pers Med. 2017 Jun 20;10:205-208. doi: 10.2147/PGPM.S107152. eCollection 2017. Review.

21.

Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003-2015: Transmitted drug resistance is due to onward transmissions.

Paraskevis D, Kostaki E, Magiorkinis G, Gargalianos P, Xylomenos G, Magiorkinis E, Lazanas M, Chini M, Nikolopoulos G, Skoutelis A, Papastamopoulos V, Antoniadou A, Papadopoulos A, Psichogiou M, Daikos GL, Oikonomopoulou M, Zavitsanou A, Chrysos G, Paparizos V, Kourkounti S, Sambatakou H, Sipsas NV, Lada M, Panagopoulos P, Maltezos E, Drimis S, Hatzakis A.

Infect Genet Evol. 2017 Oct;54:183-191. doi: 10.1016/j.meegid.2017.07.003. Epub 2017 Jul 5.

PMID:
28688977
22.

Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens.

Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Micha K, Malliori M, Pharris A, Wiessing L, Donoghoe M, Friedman S, Jarlais DD, Daikos G, Hatzakis A.

J Infect Dis. 2017 May 15;215(10):1496-1505. doi: 10.1093/infdis/jix100.

23.

Analytical characteristics and comparative evaluation of Aptima HCV quant Dx assay with the Abbott RealTime HCV assay and Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0.

Worlock A, Blair D, Hunsicker M, Le-Nguyen T, Motta C, Nguyen C, Papachristou E, Pham J, Williams A, Vi M, Vinluan B, Hatzakis A.

Virol J. 2017 Apr 4;14(1):66. doi: 10.1186/s12985-017-0727-3.

24.

Factors Associated with HIV Testing and HIV Treatment Adherence: A Systematic Review.

Detsis M, Tsioutis C, Karageorgos SA, Sideroglou T, Hatzakis A, Mylonakis E.

Curr Pharm Des. 2017;23(18):2568-2578. doi: 10.2174/1381612823666170329125820. Review.

PMID:
28356038
25.

Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, Hatzakis A.

Addiction. 2017 Jul;112(7):1290-1299. doi: 10.1111/add.13764. Epub 2017 Feb 17.

26.

A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP).

Nikolopoulos GK, Pavlitina E, Muth SQ, Schneider J, Psichogiou M, Williams LD, Paraskevis D, Sypsa V, Magiorkinis G, Smyrnov P, Korobchuk A, Vasylyeva TI, Skaathun B, Malliori M, Kafetzopoulos E, Hatzakis A, Friedman SR.

Sci Rep. 2016 Dec 5;6:38100. doi: 10.1038/srep38100.

27.

Reducing HIV infection in people who inject drugs is impossible without targeting recently-infected subjects.

Vasylyeva TI, Friedman SR, Lourenco J, Gupta S, Hatzakis A, Pybus OG, Katzourakis A, Smyrnov P, Karamitros T, Paraskevis D, Magiorkinis G.

AIDS. 2016 Nov 28;30(18):2885-2890.

28.

Utility and applicability of the "Childhood Obesity Risk Evaluation" (CORE)-index in predicting obesity in childhood and adolescence in Greece from early life: the "National Action Plan for Public Health".

Manios Y, Vlachopapadopoulou E, Moschonis G, Karachaliou F, Psaltopoulou T, Koutsouki D, Bogdanis G, Carayanni V, Hatzakis A, Michalacos S.

Eur J Pediatr. 2016 Dec;175(12):1989-1996. Epub 2016 Oct 29.

PMID:
27796510
29.

Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece.

Nikolopoulos GK, Katsoulidou A, Kantzanou M, Rokka C, Tsiara C, Sypsa V, Paraskevis D, Psichogiou M, Friedman S, Hatzakis A.

Epidemiol Infect. 2017 Jan;145(2):401-412. Epub 2016 Oct 26.

PMID:
27780490
30.

Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0.

Hatzakis A, Papachristou H, Nair SJ, Fortunko J, Foote T, Kim H, Peling TL, Worlock AJ.

Virol J. 2016 Oct 21;13(1):176.

31.

HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area.

Papachristou E, Tsagkovits A, Zavitsanou A, Hatzakis A, Paraskevis D.

Infect Genet Evol. 2016 Nov;45:415-419. doi: 10.1016/j.meegid.2016.10.003. Epub 2016 Oct 6.

PMID:
27721034
32.

A contaminant-free assessment of Endogenous Retroviral RNA in human plasma.

Karamitros T, Paraskevis D, Hatzakis A, Psichogiou M, Elefsiniotis I, Hurst T, Geretti AM, Beloukas A, Frater J, Klenerman P, Katzourakis A, Magiorkinis G.

Sci Rep. 2016 Sep 19;6:33598. doi: 10.1038/srep33598.

33.

Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.

Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A.

J Gastroenterol Hepatol. 2017 Feb;32(2):466-472. doi: 10.1111/jgh.13485.

PMID:
27403912
34.

Molecular epidemiology of HIV-1 infection in Europe: An overview.

Beloukas A, Psarris A, Giannelou P, Kostaki E, Hatzakis A, Paraskevis D.

Infect Genet Evol. 2016 Dec;46:180-189. doi: 10.1016/j.meegid.2016.06.033. Epub 2016 Jun 16. Review.

PMID:
27321440
35.

The application of HIV molecular epidemiology to public health.

Paraskevis D, Nikolopoulos GK, Magiorkinis G, Hodges-Mameletzis I, Hatzakis A.

Infect Genet Evol. 2016 Dec;46:159-168. doi: 10.1016/j.meegid.2016.06.021. Epub 2016 Jun 14. Review.

PMID:
27312102
36.

The global spread of HIV-1 subtype B epidemic.

Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, Lawyer G, Hamouda O, Struck D, Vercauteren J, Wensing A, Alexiev I, Åsjö B, Balotta C, Gomes P, Camacho RJ, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kostrikis LG, Lepej SJ, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Stylianou DC, Boucher CAB; SPREAD program, Nikolopoulos G, Vasylyeva T, Friedman SR, van de Vijver D, Angarano G, Chaix ML, de Luca A, Korn K, Loveday C, Soriano V, Yerly S, Zazzi M, Vandamme AM, Paraskevis D.

Infect Genet Evol. 2016 Dec;46:169-179. doi: 10.1016/j.meegid.2016.05.041. Epub 2016 Jun 2.

37.

Biological Warfare Plan in the 17th Century—the Siege of Candia, 1648–1669.

Thalassinou E, Tsiamis C, Poulakou-Rebelakou E, Hatzakis A.

Emerg Infect Dis. 2015 Dec;21(12):2148-53.

38.

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.

Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A.

J Viral Hepat. 2016 Feb;23 Suppl 1:1-12. doi: 10.1111/jvh.12493.

PMID:
26809941
39.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

40.

Estimating HCV disease burden - volume 3 (editorial).

Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H.

J Viral Hepat. 2015 Dec;22 Suppl 4:1-3. doi: 10.1111/jvh.12473. No abstract available.

PMID:
26513444
41.

Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples.

Giannou FK, Tsiara CG, Nikolopoulos GK, Talias M, Benetou V, Kantzanou M, Bonovas S, Hatzakis A.

Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):489-99. doi: 10.1586/14737167.2016.1102635. Epub 2015 Oct 21. Review.

PMID:
26488070
42.

How do economic crises affect migrants' risk of infectious disease? A systematic-narrative review.

Kentikelenis A, Karanikolos M, Williams G, Mladovsky P, King L, Pharris A, Suk JE, Hatzakis A, McKee M, Noori T, Stuckler D.

Eur J Public Health. 2015 Dec;25(6):937-44. doi: 10.1093/eurpub/ckv151. Epub 2015 Aug 28. Review.

43.

HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals.

Nikolopoulos GK, Paraskevis D, Psichogiou M, Hatzakis A.

J Med Virol. 2016 Mar;88(3):466-73. doi: 10.1002/jmv.24357. Epub 2015 Aug 27.

PMID:
26288334
44.

Enhanced HIV-1 surveillance using molecular epidemiology to study and monitor HIV-1 outbreaks among intravenous drug users (IDUs) in Athens and Bucharest.

Paraskevis D, Paraschiv S, Sypsa V, Nikolopoulos G, Tsiara C, Magiorkinis G, Psichogiou M, Flampouris A, Mardarescu M, Niculescu I, Batan I, Malliori M, Otelea D, Hatzakis A.

Infect Genet Evol. 2015 Oct;35:109-21. doi: 10.1016/j.meegid.2015.08.004. Epub 2015 Aug 4.

PMID:
26247720
45.

Dating the origin of hepatitis B virus reveals higher substitution rate and adaptation on the branch leading to F/H genotypes.

Paraskevis D, Angelis K, Magiorkinis G, Kostaki E, Ho SY, Hatzakis A.

Mol Phylogenet Evol. 2015 Dec;93:44-54. doi: 10.1016/j.ympev.2015.07.010. Epub 2015 Jul 26.

PMID:
26220838
46.

Network Characteristics of People Who Inject Drugs Within a New HIV Epidemic Following Austerity in Athens, Greece.

Tsang MA, Schneider JA, Sypsa V, Schumm P, Nikolopoulos GK, Paraskevis D, Friedman SR, Malliori M, Hatzakis A.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):499-508. doi: 10.1097/QAI.0000000000000665.

47.

Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme.

Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, Wiessing L, van de Laar M, Donoghoe M, Heckathorn DD, Friedman SR, Des Jarlais DC.

Addiction. 2015 Sep;110(9):1453-67. doi: 10.1111/add.12999. Epub 2015 Jul 14.

48.

The interferon receptor-1 promoter polymorphisms affect the outcome of Caucasians with HBeAg-negative chronic HBV infection.

Karamitros T, Papatheodoridis G, Dimopoulou E, Papageorgiou MV, Paraskevis D, Magiorkinis G, Sypsa V, Hatzakis A.

Liver Int. 2015 Dec;35(12):2506-13. doi: 10.1111/liv.12859. Epub 2015 May 17.

PMID:
25939635
49.

Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

Locarnini S, Hatzakis A, Chen DS, Lok A.

J Hepatol. 2015 Apr;62(1 Suppl):S76-86. doi: 10.1016/j.jhep.2015.01.018. Review.

50.

National income inequality and declining GDP growth rates are associated with increases in HIV diagnoses among people who inject drugs in Europe: a panel data analysis.

Nikolopoulos GK, Fotiou A, Kanavou E, Richardson C, Detsis M, Pharris A, Suk JE, Semenza JC, Costa-Storti C, Paraskevis D, Sypsa V, Malliori MM, Friedman SR, Hatzakis A.

PLoS One. 2015 Apr 15;10(4):e0122367. doi: 10.1371/journal.pone.0122367. eCollection 2015.

Supplemental Content

Loading ...
Support Center